Program Goals Basal Cell Cancer Basal Cell Cancer: Beyond Surgery.

Slides:

Advertisements

Similar presentations

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Advertisements

Advances and Emerging Therapy for Lung Cancer

Patched is a 12 pass transmembrane receptor: Patched is the receptor for the key signaling protein Hedgehog.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-

Emerging Trends in the Treatment of Advanced Basal Cell Carcinoma

Systemic treatment of advanced cutaneous squamous and basal cell carcinomas.

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Neoadjuvant Therapy for HER2-Positive Breast Cancer

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Post-autologous Transplant Therapy for Hodgkin Lymphoma

An Endocrinology Clinic in Dyslipidemia

Activity Goals Incidence of Basal Cell Carcinoma (BCC)

Her2-positive breast cancer: updating current best practice

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Overall Program Goals. Overall Program Goals Current Approaches.

RAI-Refractory Thyroid Cancer: Optimizing Treatment With Multikinase Inhibitors.

Metastatic Renal Cell Carcinoma

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Cancer Stem Cell Therapies in Gastrointestinal Cancers

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Definitions: Seizure, Epilepsy, Epilepsy Syndrome

Activity Goals. Activity Goals Discussion Topics.

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Beyond Statin Therapy.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Locally Advanced NSCLC Implementing Innovation

Translating Atopic Dermatitis

Managing gBRCA-Positive Metastatic Breast Cancer

VTE Treatment Conventional Approach

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Treatment of HR+ Breast Cancer: A Clinical Update

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Immunotherapy for cSCC

Personalized Therapy in Relapsed or Refractory CLL

Cohort Studies (and Skin Cancer) Never Come Alone

Controversias de Temas de Actualidad: ¿Sería Necesario Modificar el Desarrollo Clínico de los Nuevos Fármacos? a Favor Manuel Hidalgo, M.D., Ph.D.

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Treatment of Locally Advanced Pancreatic Cancer

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Volume 4, Issue 5, Pages (June 2018)

Martin M et al. Proc SABCS 2012;Abstract S1-7.

Challenges in LA SCCHN.

Volume 4, Issue 1, Pages (January 2018)

Strengthening Lung Cancer Team Connections to Improve Outcomes With Immunotherapy.

Assessing the Burden of Hyperkalemia

Educational Objectives

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Assessing the Burden of Hyperkalemia

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

PCSK9 Inhibitors and Statin Intolerance

Moving Care Forward in Advanced Gastric Cancer

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Spontaneous resolution of advanced basal cell carcinoma after short-pulse treatment with hedgehog pathway inhibitor Audrey A. Jacobsen, BA, John Strasswimmer,

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib Anne Lynn S. Chang, MD,

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Program Goals

Basal Cell Cancer

Basal Cell Cancer: Beyond Surgery

How Do We Determine That Surgery is Not the Best Option for Basal Cell Cancer?

Case 1: Josephine

Definition of Advanced BCC

Management of Advanced BCC

Adjuvant Therapies Prior to 2012

Smoothened Inhibitors for BCC

EVIRANCE Trial: Phase 2

Vismodegib: Toxicity Prevalence Over Time

BOLT Trial: Phase 2

Sonidegib: Safety

Managing Adverse Effects Multidisciplinary Team

Neoadjuvant Therapy With Smoothened Inhibitors

Case 2: Martin

Basal Cell Nevus Syndrome: Clinical Criteria

Vismodegib in BCNS

Vismodegib in BCNS: Efficacy

Hedgehog Inhibitors in BCNS Managing Side Effects

Abbreviations